Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Taxotere
TAXOTERE 20 mg/0.5 mL concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 11
HOS-084525 · Präparat HOS-083047
Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with metastatic
prostate cancer. Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4.
No statistically significant effect of prednisone on the pharmacokinetics of docetaxel was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 7a86ffe04c9d854ec7ff58f6c6fb15794ace3c4d1a11379af6cf443cf6096284 · Zeichen 1274–1565 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 80 mg/2 mL concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 55
HOS-084651 · Präparat HOS-083047
Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with metastatic
prostate cancer. Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4.
No statistically significant effect of prednisone on the pharmacokinetics of docetaxel was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 7a86ffe04c9d854ec7ff58f6c6fb15794ace3c4d1a11379af6cf443cf6096284 · Zeichen 1274–1565 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 20 mg/1 mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 100
HOS-084765 · Präparat HOS-083047
Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with metastatic
prostate cancer. Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4.
No statistically significant effect of prednisone on the pharmacokinetics of docetaxel was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 7a86ffe04c9d854ec7ff58f6c6fb15794ace3c4d1a11379af6cf443cf6096284 · Zeichen 1274–1565 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 80 mg/4 mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 144
HOS-084877 · Präparat HOS-083047
Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with metastatic
prostate cancer. Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4.
No statistically significant effect of prednisone on the pharmacokinetics of docetaxel was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 7a86ffe04c9d854ec7ff58f6c6fb15794ace3c4d1a11379af6cf443cf6096284 · Zeichen 1274–1565 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 160 mg/8 mL concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 189
HOS-084987 · Präparat HOS-083047
Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with metastatic
prostate cancer. Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4.
No statistically significant effect of prednisone on the pharmacokinetics of docetaxel was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 7a86ffe04c9d854ec7ff58f6c6fb15794ace3c4d1a11379af6cf443cf6096284 · Zeichen 1274–1565 im Abschnitt
Wechselwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 12–13
HOS-112772 · Präparat HOS-093755
12
A drug-drug interaction study assessing the effect of melphalan-prednisone on the pharmacokinetics of
bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 17% based on data
from 21 patients. This is not considered clinically relevant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage d4d334dffeefee9aee3bec75ac790615ef7a8f36adee5f3133b313c5c437df90 · Zeichen 1742–2005 im Abschnitt
Wechselwirkungen · Velcade
VELCADE 3.5 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 44
HOS-112805 · Präparat HOS-093755
A drug-drug interaction study assessing the effect of melphalan-prednisone on the pharmacokinetics of
bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 17% based on data
from 21 patients. This is not considered clinically relevant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 9e907f51e48442d1b2e301d7690958ff791903a16ae93aa6d76a2b4cca6ab4bd · Zeichen 1746–2005 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 19–20
HOS-116394 · Präparat HOS-094447
19
ANTIPSYCHOTICS/NEUROLEPTICS
Quetiapine Not studied. Boosted PREZISTA is Concomitant administration of
expected to increase these antipsychotic boosted PREZISTA and quetiapine
plasma concentrations. is contraindicated as it may
(CYP3A inhibition) increase quetiapine-related
toxicity. Increased concentrations
of quetiapine may lead to coma
(see section 4.3).
Perphenazine Not studied. Boosted PREZISTA is A dose decrease may be needed for
Risperidone expected to increase these antipsychotic these drugs when co-administered
Thioridazine plasma concentrations. with boosted PREZISTA.
(CYP3A, CYP2D6 and/or P-gp
Lurasidone inhibition) Concomitant administration of
Pimozide boosted PREZISTA and
Sertindole lurasidone, pimozide or sertindole
is contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted PREZISTA is Clinical monitoring is
Metoprolol expected to increase these β-blocker recommended when
Timolol plasma concentrations. co-administering boosted
(CYP2D6 inhibition) PREZISTA with β-blockers. A
lower dose of the β-blocker should
be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted PREZISTA can be Clinical monitoring of therapeutic
Diltiazem expected to increase the plasma and adverse effects is
Felodipine concentrations of calcium channel recommended when these
Nicardipine blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with boosted
Verapamil PREZISTA.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of boosted
metabolised by CYP3A ritonavir 100 mg capsules twice daily PREZISTA and corticosteroids (all
(including were co-administered with 50 g routes of administration) that are
betamethasone, intranasal fluticasone propionate (4 times metabolised by CYP3A may
budesonide, fluticasone, daily) for 7 days in healthy subjects, increase the risk of development of
mometasone, prednisone, fluticasone propionate plasma systemic corticosteroid effects,
triamcinolone) concentrations increased significantly, including Cushing’s syndrome and
whereas the intrinsic cortisol levels adrenal suppression.
decreased by approximately 86% (90%
CI 82-89%). Greater effects may be Co-administration with CYP3A-
expected when fluticasone is inhaled. metabolised corticosteroids is not
Systemic corticosteroid effects including recommended unless the potential
Cushing’s syndrome and adrenal benefit to the patient outweighs the
suppression have been reported in risk, in which case patients should
patients receiving ritonavir and inhaled or be monitored for systemic
intranasally administered fluticasone. The corticosteroid effects.
effects of high fluticasone systemic
exposure on ritonavir plasma levels are Alternative corticosteroids which
unknown. are less dependent on CYP3A
metabolism e.g. beclomethasone
Other corticosteroids: interaction not should be considered, particularly
studied. Plasma concentrations of these for long term use.
medicinal products may be increased
when co-administered with boosted
PREZISTA, resulting in reduced serum
cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with boosted
(CYP3A induction) PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) lead (HOS-085592) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 06bb26e6737c57cc3c74485aceb2076b3feb5ff5bad566ac99081f05e0924029 · Zeichen 52002–57572 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61–62
HOS-116527 · Präparat HOS-094447
61
Perphenazine Not studied. PREZISTA is expected to A dose decrease may be needed for
Risperidone increase these antipsychotic plasma these drugs when co-administered
Thioridazine concentrations. with PREZISTA co-administered
(CYP3A, CYP2D6 and/or P-gp with low dose ritonavir.
inhibition)
Lurasidone Concomitant administration of
Pimozide PREZISTA with low dose
Sertindole ritonavir and lurasidone, pimozide
or sertindole is contraindicated
(see section 4.3).
β-BLOCKERS
Carvedilol Not studied. PREZISTA is expected to Clinical monitoring is
Metoprolol increase these β-blocker plasma recommended when
Timolol concentrations. co-administering PREZISTA with
(CYP2D6 inhibition) β-blockers. A lower dose of the
β-blocker should be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. PREZISTA co-administered Clinical monitoring of therapeutic
Diltiazem with low dose ritonavir can be expected and adverse effects is
Felodipine to increase the plasma concentrations of recommended when these
Nicardipine calcium channel blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with PREZISTA with
Verapamil low dose ritonavir.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of PREZISTA
metabolised by CYP3A ritonavir 100 mg capsules twice daily with low dose ritonavir and
(including were co-administered with 50 g corticosteroids (all routes of
betamethasone, intranasal fluticasone propionate (4 times administration) that are
budesonide, fluticasone, daily) for 7 days in healthy subjects, metabolised by CYP3A may
mometasone, prednisone, fluticasone propionate plasma increase the risk of development of
triamcinolone) concentrations increased significantly, systemic corticosteroid effects,
whereas the intrinsic cortisol levels including Cushing’s syndrome and
decreased by approximately 86% (90% adrenal suppression.
CI 82-89%). Greater effects may be
expected when fluticasone is inhaled. Co-administration with CYP3A-
Systemic corticosteroid effects including metabolised corticosteroids is not
Cushing’s syndrome and adrenal recommended unless the potential
suppression have been reported in benefit to the patient outweighs the
patients receiving ritonavir and inhaled or risk, in which case patients should
intranasally administered fluticasone. The be monitored for systemic
effects of high fluticasone systemic corticosteroid effects.
exposure on ritonavir plasma levels are
unknown. Alternative corticosteroids which
are less dependent on CYP3A
Other corticosteroids: interaction not metabolism e.g. beclomethasone
studied. Plasma concentrations of these should be considered, particularly
medicinal products may be increased for long term use.
when co-administered with PREZISTA
with low dose ritonavir, resulting in
reduced serum cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with PREZISTA
(CYP3A induction) co-administered with low dose
ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 8b9ea54ec289adeef1a2f9f81165d44d84f0b8d5433cec6f77b7df8c89fd8286 · Zeichen 43290–48378 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 101–102
HOS-116617 · Präparat HOS-094447
101
ANTIPSYCHOTICS/NEUROLEPTICS
Quetiapine Not studied. Boosted PREZISTA is Concomitant administration of
expected to increase these antipsychotic boosted PREZISTA and quetiapine
plasma concentrations. is contraindicated as it may
(CYP3A inhibition) increase quetiapine-related
toxicity. Increased concentrations
of quetiapine may lead to coma
(see section 4.3).
Perphenazine Not studied. Boosted PREZISTA is A dose decrease may be needed for
Risperidone expected to increase these antipsychotic these drugs when co-administered
Thioridazine plasma concentrations. with boosted PREZISTA.
(CYP3A, CYP2D6 and/or P-gp
Lurasidone inhibition) Concomitant administration of
Pimozide boosted PREZISTA and
Sertindole lurasidone, pimozide or sertindole
is contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted PREZISTA is Clinical monitoring is
Metoprolol expected to increase these β-blocker recommended when
Timolol plasma concentrations. co-administering boosted
(CYP2D6 inhibition) PREZISTA with β-blockers. A
lower dose of the β-blocker should
be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted PREZISTA can be Clinical monitoring of therapeutic
Diltiazem expected to increase the plasma and adverse effects is
Felodipine concentrations of calcium channel recommended when these
Nicardipine blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with boosted
Verapamil PREZISTA.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of boosted
metabolised by CYP3A ritonavir 100 mg capsules twice daily PREZISTA and corticosteroids (all
(including were co-administered with 50 g routes of administration) that are
betamethasone, intranasal fluticasone propionate (4 times metabolised by CYP3A may
budesonide, fluticasone, daily) for 7 days in healthy subjects, increase the risk of development of
mometasone, prednisone, fluticasone propionate plasma systemic corticosteroid effects,
triamcinolone) concentrations increased significantly, including Cushing’s syndrome and
whereas the intrinsic cortisol levels adrenal suppression.
decreased by approximately 86% (90%
CI 82-89%). Greater effects may be Co-administration with CYP3A-
expected when fluticasone is inhaled. metabolised corticosteroids is not
Systemic corticosteroid effects including recommended unless the potential
Cushing’s syndrome and adrenal benefit to the patient outweighs the
suppression have been reported in risk, in which case patients should
patients receiving ritonavir and inhaled or be monitored for systemic
intranasally administered fluticasone. The corticosteroid effects.
effects of high fluticasone systemic
exposure on ritonavir plasma levels are Alternative corticosteroids which
unknown. are less dependent on CYP3A
metabolism e.g. beclomethasone
Other corticosteroids: interaction not should be considered, particularly
studied. Plasma concentrations of these for long term use.
medicinal products may be increased
when co-administered with boosted
PREZISTA, resulting in reduced serum
cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with boosted
(CYP3A induction) PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) lead (HOS-085592) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage ccb6e0bf9fbd4db134b19a5c68f5c32c6656fffa35e00c9b9b966f86c2226743 · Zeichen 51473–57044 im Abschnitt
Wechselwirkungen · Thalidomide BMS (previously Thalidomide Celgene)
Thalidomide BMS 50 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-118547 · Präparat HOS-094839
Multiple dose administration of 200 mg thalidomide q.d. for 4 days had no effect on the international
normalized ratio (INR) in healthy volunteers. However, due to the increased risk of thrombosis in
cancer patients, and a potentially accelerated metabolism of warfarin with corticosteroids, close
monitoring of INR values is advised during thalidomide-prednisone combination treatment as well as
during the first weeks after ending these treatments.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-22T16:42:00Z · SHA-256 537c04bf4162671fd0a63561bed97ea3a0b2ca75db8df09543c26a61de067575 · Passage 6fe0580b75496f0f7fe1a2881f1d06928bf0dc532a3b98ecb979e8f211f7fb62 · Zeichen 1826–2276 im Abschnitt
Gegenanzeigen · Zytiga
ZYTIGA 250 mg tablets · Abschnitt 4.3 · PDF-Seite 3–4
HOS-125273 · Präparat HOS-096037
3
- Severe hepatic impairment [Child-Pugh Class C (see sections 4.2, 4.4 and 5.2)].
- ZYTIGA with prednisone or prednisolone is contraindicated in combination with Ra-223.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisolone (HOS-086337) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T14:31:00Z · SHA-256 1cd8edc18fae83339cc466c58b27be12ff13a584e8ad30419a21aea3ec2adf1f · Passage 53fddefa70948a08eae353c64980ca8f047700b19b2b800f187432a1f21e6591 · Zeichen 221–401 im Abschnitt
Gegenanzeigen · Zytiga
ZYTIGA 500 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 26–27
HOS-125308 · Präparat HOS-096037
26
- Severe hepatic impairment [Child-Pugh Class C (see sections 4.2, 4.4 and 5.2)].
- ZYTIGA with prednisone or prednisolone is contraindicated in combination with Ra-223.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisolone (HOS-086337) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T14:31:00Z · SHA-256 1cd8edc18fae83339cc466c58b27be12ff13a584e8ad30419a21aea3ec2adf1f · Passage dcb69ac4d86d8c3d6d7cbbc6e76a9bd369cba3f01cc1e8bbec9ba2ff2ede5f29 · Zeichen 220–401 im Abschnitt
Wechselwirkungen · Zytiga
ZYTIGA 250 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-125281 · Präparat HOS-096037
Potential to affect exposures to other medicinal products
Abiraterone is an inhibitor of the hepatic drug-metabolising enzymes CYP2D6 and CYP2C8.
In a study to determine the effects of abiraterone acetate (plus prednisone) on a single dose of the
CYP2D6 substrate dextromethorphan, the systemic exposure (AUC) of dextromethorphan was
increased approximately 2.9 fold. The AUC24 for dextrorphan, the active metabolite of
dextromethorphan, increased approximately 33%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dextromethorphan (HOS-109265) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T14:31:00Z · SHA-256 1cd8edc18fae83339cc466c58b27be12ff13a584e8ad30419a21aea3ec2adf1f · Passage 15136500264c0b88f2cb2faa18da10820e5ad9c92938f5a87d0509be9b46c066 · Zeichen 1097–1563 im Abschnitt
Wechselwirkungen · Zytiga
ZYTIGA 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-125313 · Präparat HOS-096037
Potential to affect exposures to other medicinal products
Abiraterone is an inhibitor of the hepatic drug-metabolising enzymes CYP2D6 and CYP2C8.
In a study to determine the effects of abiraterone acetate (plus prednisone) on a single dose of the
CYP2D6 substrate dextromethorphan, the systemic exposure (AUC) of dextromethorphan was
increased approximately 2.9 fold. The AUC24 for dextrorphan, the active metabolite of
dextromethorphan, increased approximately 33%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dextromethorphan (HOS-109265) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T14:31:00Z · SHA-256 1cd8edc18fae83339cc466c58b27be12ff13a584e8ad30419a21aea3ec2adf1f · Passage 15136500264c0b88f2cb2faa18da10820e5ad9c92938f5a87d0509be9b46c066 · Zeichen 1097–1563 im Abschnitt
Wechselwirkungen · Docetaxel Kabi
DOCETAXEL KABI 20 mg/1 ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 11
HOS-214506 · Präparat HOS-155350
Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with metastatic
prostate cancer. Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4.
No statistically significant effect of prednisone on the pharmacokinetics of docetaxel was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage 7a86ffe04c9d854ec7ff58f6c6fb15794ace3c4d1a11379af6cf443cf6096284 · Zeichen 1488–1779 im Abschnitt
Wechselwirkungen · Docetaxel Kabi
DOCETAXEL KABI 80 mg/4 ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 57
HOS-214632 · Präparat HOS-155350
Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with metastatic
prostate cancer. Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4.
No statistically significant effect of prednisone on the pharmacokinetics of docetaxel was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage 7a86ffe04c9d854ec7ff58f6c6fb15794ace3c4d1a11379af6cf443cf6096284 · Zeichen 1488–1779 im Abschnitt
Wechselwirkungen · Docetaxel Kabi
DOCETAXEL KABI 120 mg/6 ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 103
HOS-214750 · Präparat HOS-155350
Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with metastatic
prostate cancer. Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4.
No statistically significant effect of prednisone on the pharmacokinetics of docetaxel was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage 7a86ffe04c9d854ec7ff58f6c6fb15794ace3c4d1a11379af6cf443cf6096284 · Zeichen 1488–1779 im Abschnitt
Wechselwirkungen · Docetaxel Kabi
DOCETAXEL KABI 160 mg/8 ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 149
HOS-214868 · Präparat HOS-155350
Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with metastatic
prostate cancer. Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4.
No statistically significant effect of prednisone on the pharmacokinetics of docetaxel was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage 7a86ffe04c9d854ec7ff58f6c6fb15794ace3c4d1a11379af6cf443cf6096284 · Zeichen 1487–1778 im Abschnitt
Wechselwirkungen · Docetaxel Kabi
DOCETAXEL KABI 180 mg/9 ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 195
HOS-214983 · Präparat HOS-155350
Docetaxel pharmacokinetics in the presence of prednisone was studied in patients with metastatic
prostate cancer. Docetaxel is metabolised by CYP3A4 and prednisone is known to induce CYP3A4.
No statistically significant effect of prednisone on the pharmacokinetics of docetaxel was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage 7a86ffe04c9d854ec7ff58f6c6fb15794ace3c4d1a11379af6cf443cf6096284 · Zeichen 1488–1779 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.